| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/03/2013 | CA2840577A1 Soluble integrin .alpha.4 mutant |
| 01/03/2013 | CA2840211A1 Method of administration and treatment |
| 01/03/2013 | CA2840143A1 Composition comprising inhibitors of irs-1 and of vegf |
| 01/03/2013 | CA2839938A1 Photoactivatable receptors and their uses |
| 01/03/2013 | CA2839869A1 Anti-erbb3 antibobies in combination with paclitaxel for treatment of gynecological cancers |
| 01/03/2013 | CA2839451A1 Methods and compositions for treatment of cancer and autoimmune disease |
| 01/03/2013 | CA2838875A1 Camptothecin derivative, method for preparing same, pharmaceutical composition and use thereof |
| 01/03/2013 | CA2837453A1 Crystals of glycine derivative and pharmaceutical use thereof |
| 01/03/2013 | CA2836914A1 Acid-labile lipophilic prodrugs of cancer chemotherapeutic agents |
| 01/02/2013 | EP2540828A1 Composition comprising inhibitors of IRS-1 and of VEGF |
| 01/02/2013 | EP2540827A1 Anti-icam3 antibody and use thereof |
| 01/02/2013 | EP2540745A1 Fully humanized anti-her2 antibody, preparation method and use thereof |
| 01/02/2013 | EP2540744A1 Fully human monoclonal antibody to vegf, preparation method and use thereof |
| 01/02/2013 | EP2540741A1 Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| 01/02/2013 | EP2540737A1 Use of multivalent synthetic ligands of surface nucleolin for the treatment of inflammation |
| 01/02/2013 | EP2540728A1 Heterocyclic compound |
| 01/02/2013 | EP2540320A1 Leptomycin derivatives |
| 01/02/2013 | EP2540319A1 Antitumoral bioconjugates of hyaluronic acid or its derivatives obtained by indirect chemical conjugation |
| 01/02/2013 | EP2539448A1 Protein c zymogen and methods of use thereof to prevent cancer metastases |
| 01/02/2013 | EP2539368A1 Cancer vaccine |
| 01/02/2013 | EP2539357A2 Methods and compositions for the detection and treatment of cancer involving mirnas and mirna inhibitors and targets |
| 01/02/2013 | EP2539347A2 Trimethoxyphenyl inhibitors of tyrosine kinase |
| 01/02/2013 | EP2539346A1 Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions |
| 01/02/2013 | EP2539345A1 4 - [cycloalkyloxy (hetero) arylamino]thieno [2, 3 - d]pyrimidines having mnkl/ mnk2 inhibiting activity for pharmaceutical compositions |
| 01/02/2013 | EP2539344A1 Halogen or cyano substituted thieno [2,3-d]pyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions |
| 01/02/2013 | EP2539339A2 10'-fluorinated vinca alkaloids provide enhanced biological activity against mdr cancer cells |
| 01/02/2013 | EP2539337A1 Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use |
| 01/02/2013 | EP2539333A1 Dimeric iap inhibitors |
| 01/02/2013 | EP2539328A1 Novel water soluble furoxan derivatives having antitumor activity |
| 01/02/2013 | EP2539327A1 Oxadiazole compounds, their preparation and use |
| 01/02/2013 | EP2538981A1 Compositions and methods for the diagnosis and treatment of tumor |
| 01/02/2013 | EP2538977A1 Dna dendrimers as thermal ablation devices |
| 01/02/2013 | EP2538944A2 Method for treating brain cancer |
| 01/02/2013 | EP2538935A2 Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with 7-hydroxystaurosporine |
| 01/02/2013 | EP2538933A2 Use of essential oil of oregano or rosewood in the treatment of malign keratosis |
| 01/02/2013 | EP2538932A2 Use of essential oil of oregano or rosewood in the treatment of actinic keratosis |
| 01/02/2013 | EP2182949B1 (2s,3r)-n-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof |
| 01/02/2013 | CN1886148B Selective inhibition of NF-kB activation by peptides designed to disrupt NEMO oligomerization |
| 01/02/2013 | CN1854157B Antibodies to insulin-like growth factor i receptor |
| 01/02/2013 | CN1658899B Modified CEA nucleic acid and expression vectors |
| 01/02/2013 | CN1454215B Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
| 01/02/2013 | CN102858959A Oncolytic rhabdovirus |
| 01/02/2013 | CN102858804A Neutralizing prolactin receptor antibodies and their therapeutic use |
| 01/02/2013 | CN102858803A Neutralizing prolactin receptor antibodies and their therapeutic use |
| 01/02/2013 | CN102858801A Neutralizing prolactin receptor antibodies and their therapeutic use |
| 01/02/2013 | CN102858782A 4 - [cycloalkyloxy (hetero) arylamino] thieno [2, 3 - d] pyrimidines having mnkl/ mnk2 inhibiting activity for pharmaceutical compositions |
| 01/02/2013 | CN102858770A Bicyclic Compounds And Their Uses As Dual C-src / Jak Inhibitors |
| 01/02/2013 | CN102858769A Pyrazolopyridine kinase inhibitors |
| 01/02/2013 | CN102858768A Substituted triazolopyridines |
| 01/02/2013 | CN102858767A Aminopyrimidines as SYK inhibitors |
| 01/02/2013 | CN102858765A Pyrazolyl quinazoline kinase inhibitors |
| 01/02/2013 | CN102858764A Pyrimidinyl indole compounds |
| 01/02/2013 | CN102858754A RAF inhibitor compounds and methods of use thereof |
| 01/02/2013 | CN102858367A Composite body for antigen or drug delivery |
| 01/02/2013 | CN102858362A SPARC angiogenic domain and methods of use |
| 01/02/2013 | CN102858337A Diindolylmethane-based drug for the treatment of hyperplastic and inflammatory diseases |
| 01/02/2013 | CN102858335A Use of ERBB3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| 01/02/2013 | CN102858323A Anticancer drug delivery system using ph-sensitive metal nanoparticles |
| 01/02/2013 | CN102851740A Fluorinated docetaxel crystal and its preparation method |
| 01/02/2013 | CN102851345A Preparation method for chlorella antitumor polypeptide |
| 01/02/2013 | CN102851344A Preparation method for spirulina antitumor polypeptide |
| 01/02/2013 | CN102851343A Preparation method for chlorella antitumor polypeptide |
| 01/02/2013 | CN102851315A Application of recombinant adenovirus TMEM166 as gene therapeutic drug in inhibiting tumor |
| 01/02/2013 | CN102851296A Anti-liver cancer protein pp3501, its preparation method and application |
| 01/02/2013 | CN102851169A Black food health-care yellow rice wine and production technology thereof |
| 01/02/2013 | CN102850469A O-carboxymethyl chitosan-stearic acid polymer as well as synthesis method thereof and application of polymer |
| 01/02/2013 | CN102850465A Preparation method of sargassum fusiforme selenium polysaccharide |
| 01/02/2013 | CN102850462A Lactarius deliciosus polysaccharide and application thereof |
| 01/02/2013 | CN102850458A Novel recombined dual-function fusion protein and its preparation method and application |
| 01/02/2013 | CN102850456A Humanized monoclonal antibody of vascular endothelial growth factor as well as preparation method and application thereof |
| 01/02/2013 | CN102850455A Anti-glypican-3 antibody |
| 01/02/2013 | CN102850443A Integrin blocker polypeptides and application thereof |
| 01/02/2013 | CN102850436A Growth hormone releasing peptides |
| 01/02/2013 | CN102850435A Peptide vaccines for cancers expressing MPHOSP1 or DEPDC1 polypeptides |
| 01/02/2013 | CN102850434A Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides |
| 01/02/2013 | CN102850433A Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides |
| 01/02/2013 | CN102850427A Tanshinone IIA derivative and preparation and application thereof |
| 01/02/2013 | CN102850422A Dexamethasone small-molecular hydrogel drug delivery system and preparation method thereof |
| 01/02/2013 | CN102850400A Camptothecin derivative, and preparation method, pharmaceutical composition and use thereof |
| 01/02/2013 | CN102850397A Multi-target antitumor compounds and preparation method and application thereof |
| 01/02/2013 | CN102850372A Yarrow sesquiterpene lactone compound as well as extraction method and application of compound |
| 01/02/2013 | CN102850369A Nitrogen monoxide donor-type oridonin 1,4-hydroxyl-modified derivative, and its preparation method and application |
| 01/02/2013 | CN102850364A Derivative of Dysosma versipellis, and composition, preparation method and use thereof |
| 01/02/2013 | CN102850363A Irinotecan hydrochloride compound and pharmaceutical composition thereof |
| 01/02/2013 | CN102850344A Medicinal application of penehyclidine optical isomer derivative in anti-tumor |
| 01/02/2013 | CN102850337A Multi-azole linked spirorenone compound and preparation method and application thereof |
| 01/02/2013 | CN102850328A Pyridine chemical, its preparation method, and pharmaceutical composition containing the chemical and application thereof |
| 01/02/2013 | CN102850324A Indole compounds |
| 01/02/2013 | CN102850301A Water-soluble paclitaxel derivates and pharmaceutical composition and medicinal application thereof |
| 01/02/2013 | CN102850283A Triazolyl-containing amino-dithio formic ether compound as well as preparation method and application of compound |
| 01/02/2013 | CN102850280A 6,7-dialkyloxy-4-substituted phenylamino quinazoline compounds and preparation methods |
| 01/02/2013 | CN102850236A Novel benzamide histone deacetylase inhibitor and application thereof |
| 01/02/2013 | CN102850203A Juglone derivative and application thereof |
| 01/02/2013 | CN102849717A Fullerol and preparation method thereof |
| 01/02/2013 | CN102847171A Gene medicine for treating liver cancer and preparation method and application thereof |
| 01/02/2013 | CN102847166A Prodrug of oridonin with polyethylene glycol serving as vector and preparation method thereof |
| 01/02/2013 | CN102847156A Fatty acid synthase inhibitor and application thereof |
| 01/02/2013 | CN102847155A Method for inhibiting tumor metastasis |
| 01/02/2013 | CN102847148A Antibodies binding to an intracellular PRL-1 OR PRL-3 polypeptide |
| 01/02/2013 | CN102847145A Method for preparing dendritic cell vaccine |